Cardinal Health vs Eli Lilly stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Cardinal Health is cheaper for its profits. Eli Lilly is more profitable, grows faster and has less debt.
Side by side
| Cardinal Health | Eli Lilly | |
|---|---|---|
| $65.0 billion | $1.29 trillion | |
| 0.7% | 31.7% | |
| +7.8% | +21.6% | |
| 41.6× | 62.3× | |
| 1.2 years | 1.1 years | |
| 34.0% | 34.8% | |
| 1.0% | 0.6% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Cardinal Health vs McKesson · Cardinal Health vs Cencora · Eli Lilly vs The Cigna Group · Eli Lilly vs Cencora · Eli Lilly vs CSL · Eli Lilly vs Danaher

